EP12.01. Tepotinib and Capmatinib in Patients with MET exon 14 Skipping NSCLC: A Matching Adjusted Indirect Comparison (MAIC) - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Boris Pfeiffer
Meta Tag
Speaker Boris Pfeiffer
Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2
matching-adjusted indirect comparison
tyrosine kinase inhibitors
MET exon 14 skipping non-small cell lung cancer
non-randomized Phase II trials
progression-free survival
overall survival
VISION trial
GEOMETRY mono-1 trial
Powered By